Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: Risks of inadvertent trivalent oral poliovirus vaccine use

BMC Infectious Diseases

Volumn 16, Issue 1, 2016, Pages

  Duintjer Tebbens, Radboud J ^a   Hampton, Lee M ^b   Thompson, Kimberly M ^a  

^a Kid Risk Inc   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Dynamic modeling; Eradication; Oral poliovirus vaccine; Polio; Risk management; Vaccine derived poliovirus

Indexed keywords

BIVALENT ORAL POLIOVIRUS VACCINE; ORAL POLIOMYELITIS VACCINE; UNCLASSIFIED DRUG; POLIOMYELITIS VACCINE;

ARTICLE; BASIC REPRODUCTION NUMBER; CIRCULATING VACCINE DERIVED POLIOVIRUS 2; CONTROLLED STUDY; DISEASE ERADICATION; DISEASE SIMULATION; DRUG USE; EPIDEMIC; HEALTH CARE PLANNING; HUMAN POLIOVIRUS 2; IMMUNIZATION; INFECTION RESISTANCE; INFECTION RISK; POLIOMYELITIS; POPULATION RESEARCH; RISK ASSESSMENT; RISK REDUCTION; ROUTINE IMMUNIZATION; SUPPLEMENTAL IMMUNIZATION ACTIVITY; TREATMENT WITHDRAWAL; VACCINATION; VIRUS TRANSMISSION; VULNERABLE POPULATION; CHILD; DISEASE OUTBREAKS; GLOBAL HEALTH; HUMAN; IMMUNOLOGY; INAPPROPRIATE PRESCRIBING; INFANT; ORGANIZATION AND MANAGEMENT; POLIOMYELITIS VIRUS; PREVENTION AND CONTROL; PROCEDURES; RISK MANAGEMENT; SEROTYPE; STATISTICS AND NUMERICAL DATA; THEORETICAL MODEL; VIROLOGY;

CHILD; DISEASE ERADICATION; DISEASE OUTBREAKS; GLOBAL HEALTH; HEALTH PLAN IMPLEMENTATION; HUMANS; INAPPROPRIATE PRESCRIBING; INFANT; MODELS, THEORETICAL; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; RISK MANAGEMENT; SEROGROUP; VACCINATION; WITHHOLDING TREATMENT;

EID: 84971525490     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-016-1537-8     Document Type: Article

References (28)

1. World Health Assembly. Poliomyelitis (resolution 68.3). Geneva: World Health Organization; 2015.
2. World Health Organization: Global Polio Eradication Initiative: Polio Eradication and Endgame Strategic Plan (2013-2018). Report number: WHO/POLIO/13.02. Geneva; 2013.
3. Immunization Systems Management Group of the Global Polio Eradication Initiative. Introduction of inactivated poliovirus vaccine and switch from trivalent to bivalent oral poliovirus vaccine - worldwide, 2013-2016. MMWR Morb Mortal Wkly Rep. 2015;64(25):669-702.
4. Global Polio Eradication Initiative; Global eradication of wild poliovirus type 2 declared [ http://www.polioeradication.org/mediaroom/newsstories/Global-eradication-of-wild-poliovirus-type-2-declared/tabid/526/news/1289/Default.aspx , accessed 30 Nov 2015]
5. Diop OM, Burns CC, Sutter RW, Wassilak SG, Kew OM. Centers for Disease C, Prevention: Update on Vaccine-Derived Polioviruses - Worldwide, January 2014-March 2015. MMWR Morb Mortal Wkly Rep. 2015;64(23):640-6.
6. Duintjer Tebbens RJ, Pallansch MA, Kim J-H, Burns CC, Kew OM, Oberste MS, Diop O, Wassilak SGF, Cochi SL, Thompson KM. Review: Oral Poliovirus Vaccine Evolution and Insights Relevant to Modeling the Risks of Circulating Vaccine-Derived Polioviruses (cVDPVs). Risk Anal. 2013;23(4):680-702.
7. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59:587-635.
8. Thompson KM, Duintjer Tebbens RJ. Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis. 2014;210 Suppl 1:S475-84.
9. Duintjer Tebbens RJ, Thompson KM. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. J Infect Dis. 2014;210 Suppl 1:S485-97.
10. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SGF, Thompson KM. An economic analysis of poliovirus risk management policy options for 2013-2052. BMC Infect Dis. 2015;15:389.
11. Duintjer Tebbens RJ, Pallansch MA, Wassilak SGF, Cochi SL, Thompson KM. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. BMC Infect Dis. 2016;16:137.
12. Duintjer Tebbens RJ, Pallansch MA, Thompson KM. Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs. BMC Infect Dis. 2015;15:379.
13. World Health Organization; GAP III: WHO Global Action Plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of oral polio vaccine use [ http://www.polioeradication.org/Portals/0/Document/Resources/PostEradication/GAPIII_2014.pdf , accessed 9 Nov 2015]
14. Duintjer Tebbens RJ, Hampton LM, Thompson KM. Implementation of coordinated global oral poliovirus vaccine serotype 2 cessation: Risks of potential non-synchronous cessation. BMC Infect Dis. 2016;16:231.
15. Murhekar MV, Dutta S, Kapoor AN, Bitragunta S, Dodum R, Ghosh P, Swamy KK, Mukhopadhyay K, Ningombam S, Parmar K, et al. Frequent exposure to suboptimal temperatures in vaccine cold-chain system in India: results of temperature monitoring in 10 states. Bull World Health Organ. 2013;91(12):906-13.
16. Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SG, Cochi SL, Thompson KM. Characterizing poliovirus transmission and evolution: Insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal. 2013;23(4):703-49.
17. Duintjer Tebbens RJ, Kalkowska DA, Wassilak SGF, Pallansch MA, Cochi SL, Thompson KM. The potential impact of expanding target age groups for polio immunization campaigns. BMC Infect Dis. 2014;14:45.
18. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, et al. Expert review on poliovirus immunity and transmission. Risk Anal. 2013;33(4):544-605.
19. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, et al. Review and assessment of poliovirus immunity and transmission: Synthesis of knowledge gaps and identification of research needs. Risk Anal. 2013;33(4):606-46.
20. Kalkowska DA, Duintjer Tebbens RJ, Grotto I, Shulman LM, Anis E, Wassilak SGF, Pallansch MA, Thompson KM. Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. J Infect Dis. 2015;211(11):1800-12.
21. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria. J Infect Dis. 2014;210 Suppl 1:S412-23.
22. van der Sanden S, Pallansch MA, van de Kassteele J, El-Sayed N, Sutter RW, Koopmans M, van der Avoort HGAM. Shedding of vaccine viruses with increased antigenic and genetic divergence after vaccination of newborns with monovalent type 1 oral poliovirus vaccine. J Virol. 2009;83(17):8693-704.
23. Onorato IM, Modlin JF, McBean MA, Thoms ML, Losonsky GA, Bernier RH. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis. 1991;163:1-6.
24. Duintjer Tebbens RJ, Pallansch MA, Wassilak SGF, Cochi SL, Thompson KM. Combinations of quality and frequency of immunization activities to stop and prevent poliovirus transmission in the high-risk area of northwest Nigeria. PLoS One. 2015;10(6):e0130123.
25. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in two high-risk areas in northern India. J Infect Dis. 2014;210 Suppl 1:S398-411.
26. Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SGF, Thompson KM. Modeling undetected live poliovirus circulation after apparent interruption of transmission: Implications for surveillance and vaccination. BMC Infect Dis. 2015;15(66):1.
27. Duintjer Tebbens RJ, Thompson KM. Managing the risk of circulating vaccine-derived poliovirus during the endgame: Oral poliovirus vaccine needs. BMC Infect Dis. 2015;15:390.
28. Global Polio Eradication Initiative; Nationwide polio immunization campaign under way in Ukraine [ http://www.polioeradication.org/mediaroom/newsstories/Nationwide-polio-immunization-campaign-under-way-in-Ukraine/tabid/526/news/1300/Default.aspx , accessed 11 Nov 2015]